The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself

Article content

Issued on behalf of Conexeu Sciences Inc.

Article content

A biotech debut out of Reno is betting that the next wave of medicine won’t replace tissue — it’ll grow it back.

Article content

Article content

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) — Energy Metal News News Commentary — Somewhere between a 3D printer, a stem cell lab, and an operating room, a quiet shift has been building in medicine. The premise is no longer to put something foreign into the body when tissue is lost. The premise is to give the body the scaffolding, the cues, and the conditions it needs to grow back what was taken — and then have that scaffolding dissolve, leaving only the patient’s own living tissue behind.

Article content

Article content

On May 21, 2026, a new Nasdaq ticker put a public-market price on that idea.

Article content

Article content

Reno-based Conexeu Sciences Inc. (Nasdaq: CNXU) opened for trading under the banner of “Architecting Bioregeneration™,” with 25,269,996 shares outstanding and 35,238,222 on a fully diluted basis. Behind the ticker is a single platform, called CXU™, that the company says can be expressed across multiple tissue-regeneration products without reformulating the underlying chemistry. One formula. One device. Many indications.

Article content

CEO Miles D. Harrison framed the moment plainly on listing day: “At Conexeu, we believe regenerative medicine requires more than incremental improvement; it requires a fundamentally different foundation.” Going public, he added, strengthens the company’s ability to keep building that foundation.

Article content

A Different Kind of Implant Conversation

Article content

The product attracting the most attention is the one with the most provocative name. Conexeu recently unveiled BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE™ — B.R.E.A.S.T.™ — a 3D-bioprinted regenerative breast matrix designed to support the body’s own tissue regeneration following mastectomy. The matrix isn’t meant to be permanent. It is intended to function as a temporary regenerative scaffold that gradually resorbs as the patient’s own tissue remodels and replaces it over time.

Article content

Article content

The positioning matters because of the gap it’s aiming at. More than 100,000 women undergo mastectomies annually in the U.S., yet many elect not to pursue reconstruction. If a scaffold-based regenerative option can offer something closer to “rebuild” than “replace,” the market it’s chasing is structurally larger than any single implant category in the field today.

Article content

Early days, of course. B.R.E.A.S.T.™ is an investigational medical device candidate whose safety and effectiveness have not been established and which has not been submitted to or reviewed by the U.S. Food and Drug Administration — the standard disclosure for a preclinical-stage company at this point in its lifecycle. The science, the IP, and the platform extensibility are what investors are weighing in the meantime.

Article content

One Platform, Many Possible Doors

Article content

Conexeu’s broader pipeline starts with a flagship product called Ten Minute Tissue™ — a CXU-based injectable extracellular matrix that remains fluid at room temperature and transitions to a stable gel in situ at body temperature within approximately ten minutes. In preclinical work, Ten Minute Tissue™ has demonstrated enhanced healing dynamics, organized scaffold formation, and a favorable (low) inflammatory profile.